Key result
Angiotensin II exacerbates intracerebral hemorrhage in mice by potentiating antithrombin, while anti-Ang II antibodies alleviate bleeding.
Why the study?
Hypertension exhibits a paradoxical prothrombotic-hemorrhagic predisposition toward cerebral infarction and intracerebral hemorrhage, but the underlying mechanism remains poorly understood.
Does Angiotensin II regulate coagulation and exacerbate intracerebral hemorrhage in mice?
Does Angiotensin II regulate coagulation and exacerbate intracerebral hemorrhage in mice?
Angiotensin II acts as a key coagulation regulator with heparin-like antithrombin activation function, suggesting that targeting the Ang II-coagulation pathway could be a novel strategy to mitigate cerebral bleeding.
Answers are grounded in this paper and cite their sources.
May exacerbate ICH via antithrombin activation in hypertensive mice; leaves open whether anti-Ang II antibodies reduce human cerebral bleeding risk.
Hypertension has paradoxical prothrombotic-hemorrhagic predisposition toward cerebral infarction and intracerebral hemorrhage (ICH), but the mechanism remains poorly understood. We observed Angiotensin II (Ang II) inhibited coagulation by activating antithrombin through heparin-like acceleration of antithrombin-thrombin interaction. Ang II allosterically modulates the 386-397 loop of antithrombin to enhance thrombin inhibition. In vivo, single injection of Ang II inhibited coagulation, alleviating thrombosis and aggravating ICH. Conversely, anti-Ang II monoclonal antibody promoted coagulation, aggravating thrombus formation and alleviating ICH. Notably, the blockage or deficiency of Ang II receptor had no significant effect on the alleviated thrombus formation or aggravated hemorrhage elicited by Ang II, suggesting the phenotypes were independent of Ang II receptor. In hypertensive mice, anti-Ang II monoclonal antibody significantly promoted coagulation and ameliorated ICH. These results identify Ang II as a key coagulation regulator with heparin-like function, suggesting that targeting Ang II-coagulation pathway could be a novel strategy to mitigate cerebral bleeding. Here, the authors show that angiotensin II acts as a key coagulation regulator with heparin-like antithrombin activation function in mediating hemorrhage. Targeting the angiotensin II coagulation pathway could be a novel strategy to mitigate cerebral bleeding events.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Intracerebral hemorrhage and thrombosis. Angiotensin II (Ang II) and anti-Ang II monoclonal antibody vs. 0.9% NaCl or IgG control was evaluated on Coagulation parameters (APTT, PT, bleeding time) and intracerebral hemorrhage hematoma volume (p=<0.0001). A single injection of Angiotensin II exacerbated intracerebral hemorrhage and inhibited coagulation in mice by potentiating antithrombin, whereas an anti-Ang II monoclonal antibody promoted coagulation and alleviated hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: